Primary platinum refractory disease
WebOct 26, 2024 · If patients had primary platinum-refractory disease or primary platinum resistance, a histologically confirmed diagnosis of epithelial ovarian carcinoma with … WebDisease status just prior to the start of the preparative regimen for hematopoietic stem cell transplantation (HSCT): Primary refractory refers to never achieving a complete …
Primary platinum refractory disease
Did you know?
WebOS is improved in patients without primary platinum refractory disease. Intermittent Rel+Nab vs Nab: ORR: 35.7 vs 35.8% PFS: 5.6 vs 3.8 months* ... Promising activity of … WebPrior to the advent of PD1/PDL1 checkpoint inhibitors, systemic chemotherapy with cisplatin-based regimens was the standard of care, leading to median survival of around 1 year. 5,6 For patients with platinum-refractory disease, the median survival was only 6–9 months. 7–10 Furthermore, up to 30%–50% of patients with metastatic UC are ineligible …
WebAmong HNC patients who had disease progression within 6 months after platinum-based chemotherapy administered for primary or recurrent disease, the median treatment … WebIn patients with relapsed ovarian cancer, the overall response rates on treatment with topotecan range from 19%-33% in platinum-sensitive patients, 14%-18% in platinum-resistant patients, and 5%-11% in platinum-refractory patients. The proportion of patients achieving stable disease ranges between 17% in refractory and 48% in sensitive patients ...
WebJan 30, 2024 · Patients with more than three prior lines were ineligible on the basis of lower activity seen in more heavily pretreated patients as part of the expansion cohort of the … WebMar 3, 2024 · PIT-565 is under clinical development by Novartis and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PIT-565’s ...
WebJun 29, 2024 · The ORR was 33% following treatment in 21 patients with platinum-resistant disease and 19% in 16 patients with platinum-refractory disease. The median duration of …
WebApr 30, 2024 · Approaching Platinum-Refractory Recurrent Ovarian Cancer. Apr 30, 2024. ... This is a patient though that actually although she has no persistent disease at the completion of primary therapy, which would be kind of the standard definition of refractory, ... hauraki weather forecastWeb•Patietnts with primary platinum-refractory disease (defined as progression during or within 4 weeks after completion of the first platinum regimen) are not eligible. • EOG of 0 to 1. • … hauraki veterinary servicesWebIndeed, treatment options in platinum refractory disease included monochemotherapy with taxanes and methotrexate, ... However, head and neck second malignancies could occurr for impaired immunosurveillance. Recurrent disease with a primary induced resistance to immunotherapy is the result of an incomplete and ineffective first immune response. hauraki property servicesWebMar 14, 2024 · Forty percent of the women had suboptimally resected stage III disease, and 26% had stage IV disease. The primary end point of the study was PFS.[Level of evidence B1] ... Responses have been observed … borderlands 2 dlc only downloadWebMar 31, 2024 · When excluding those with primary platinum-refractory disease and those who previously received 4 or more lines of therapy, intermittent relacorilant plus nab … hauraton design softwareWebSep 6, 2013 · Primary platinum-resistant: Previously untreated patients who have achieved at least a partial response to platinum-based chemotherapy but experience a relapse … borderlands 2 download pc freeWebJan 25, 2024 · Most in the study had platinum-resistant disease, while 10% in the study arm and 15% in the control arm had primary platinum-refractory disease. To enroll, ... borderlands 2 downpatcher